Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Creative Planning

Creative Planning increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,672 shares of the medical research company’s stock after purchasing an additional 180 shares during the quarter. Creative Planning’s holdings in Charles River Laboratories International were worth $920,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Tortoise Investment Management LLC lifted its holdings in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Charles River Laboratories International in the 1st quarter valued at about $41,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 193 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at about $79,000. Finally, iA Global Asset Management Inc. acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at about $87,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. The Goldman Sachs Group cut their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. StockNews.com raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. TD Cowen reduced their price objective on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. CLSA assumed coverage on shares of Charles River Laboratories International in a research note on Wednesday, October 23rd. They set an “underperform” rating and a $167.00 price objective for the company. Finally, Evercore ISI lowered shares of Charles River Laboratories International from an “outperform” rating to an “inline” rating and reduced their price objective for the company from $225.00 to $190.00 in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Price Performance

Shares of CRL opened at $180.96 on Friday. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of 21.67, a P/E/G ratio of 6.22 and a beta of 1.36. Charles River Laboratories International, Inc. has a fifty-two week low of $166.87 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The business’s 50-day moving average is $193.72 and its 200-day moving average is $209.45.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has approved a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).